← All trials
NCT05089266
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Dec 30, 2022
- Completion date
- Oct 30, 2023
- First posted
- Oct 22, 2021
- Last posted
- Oct 22, 2021
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Shanghai Cell Therapy Group Co.,LtdLead sponsor
- NO.17 Panjiayuan NanliOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.